|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
GBD 2015 Mortality and Causes of Death
Collaborators: Global, regional, and national life expectancy,
all-cause mortality, and cause-specific mortality for 249 causes of
death, 1980–2015: A systematic analysis for the Global Burden of
disease study 2015. Lancet. 388:1459–1544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kelly C and Cassidy J: Chemotherapy in
metastatic colorectal cancer. Surg Oncol. 16:65–70. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bouche O, Conroy T, Michel P, Penna C and
Tournigand C: Metastatic colorectal cancer. Gastroenterol Clin
Biol. 30:2S30–2S42. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yau T, Chan P, Ching Chan Y, Wong BC,
Liang R and Epstein RJ: Current management of metastatic colorectal
cancer-the evolving impact of targeted drug therapies. Aliment
Pharmacol Ther. 27:997–1005. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilkes G and Hartshorn K: Clinical update:
Colon, rectal, and anal cancers. Semin Oncol Nurs. 28:e1–e22. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tran NH, Cavalcante LL, Lubner SJ,
Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA and Deming DA:
Precision medicine in colorectal cancer: The molecular profile
alters treatment strategies. Ther Adv Med Oncol. 7:252–262. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lichtenstein P, Holm NV, Verkasalo PK,
Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A and Hemminki
K: Environmental and heritable factors in the causation of
cancer-analyses of cohorts of twins from Sweden, Denmark, and
Finland. N Engl J Med. 343:78–85. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wood LD, Parsons DW, Jones S, Lin J,
Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The
genomic landscapes of human breast and colorectal cancers. Science.
318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sjöblom T, Jones S, Wood LD, Parsons DW,
Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al:
The consensus coding sequences of human breast and colorectal
cancers. Science. 314:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nassiri M, Kooshyar MM, Roudbar Z, Mahdavi
M and Doosti M: Genes and SNPs associated with non-hereditary and
hereditary colorectal cancer. Asian Pac J Cancer Prev.
14:5609–5614. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hampel H: Genetic testing for hereditary
colorectal cancer. Surg Oncol Clin N Am. 18:687–703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cancer Genome Atlas Research Network;
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas Pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin Y, Golovnina K, Chen ZX, Lee HN,
Negron YL, Sultana H, Oliver B and Harbison ST: Comparison of
normalization and differential expression analyses using RNA-Seq
data from 726 individual Drosophila melanogaster. BMC
Genomics. 17:282016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Coffey JC and Dockery P: Colorectal
cancer: Surgery for colorectal cancer-standardization required. Nat
Rev Gastroenterol Hepatol. 13:256–257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sauer R, Fietkau R, Wittekind C, Rödel C,
Martus P, Hohenberger W, Tschmelitsch J, Sabitzer H, Karstens JH,
Becker H, et al: Adjuvant vs. neoadjuvant radiochemotherapy for
locally advanced rectal cancer: The German trial CAO/ARO/AIO-94.
Colorectal Dis. 5:406–415. 2003.
|
|
17
|
Benson AB Rd: Should we consider adjuvant
therapy for rectal cancer after neoadjuvant chemoradiotherapy? Clin
Adv Hematol Oncol. 14:778–781. 2016.PubMed/NCBI
|
|
18
|
Arnold D and Seufferlein T: Targeted
treatments in colorectal cancer: State of the art and future
perspectives. Gut. 59:838–858. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seeber A and Gastl G: Targeted therapy of
colorectal cancer. Oncol Res Treat. 39:796–802. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pai SG and Fuloria J: Novel therapeutic
agents in the treatment of metastatic colorectal cancer. World J
Gastrointest Oncol. 8:99–104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu YW, Zhang HF, Liang R, Xie ZR, Luo HY,
Zeng YJ, Xu Y, Wang LM, Kong XY and Wang KH: Colorectal cancer
genetic heterogeneity delineated by multi-region sequencing. PLoS
One. 11:e01526732016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sonachalam M, Shen J, Huang H and Wu X:
Systems biology approach to identify gene network signatures for
colorectal cancer. Front Genet. 3:802012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee H, Palm J, Grimes SM and Ji HP: The
cancer genome atlas clinical explorer: A web and mobile interface
for identifying clinical-genomic driver associations. Genome Med.
7:1122015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Z, Jensen MA and Zenklusen JC: A
practical guide to the cancer genome atlas (TCGA). Methods Mol
Biol. 1418:111–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hartman M, Loy EY, Ku CS and Chia KS:
Molecular epidemiology and its current clinical use in cancer
management. Lancet Oncol. 11:383–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feige E, Chen A and Motro B: Nurit, a
novel leucine-zipper protein, expressed uniquely in the spermatid
flower-like structure. Mech Dev. 117:369–377. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alber T: Structure of the leucine zipper.
Curr Opin Genet Dev. 2:205–210. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takemaru K, Yamaguchi S, Lee YS, Zhang Y,
Carthew RW and Moon RT: Chibby, a nuclear beta-catenin-associated
antagonist of the Wnt/Wingless pathway. Nature. 422:905–909. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Letwin K, Mizzen L, Motro B, Ben-David Y,
Bernstein A and Pawson T: A mammalian dual specificity protein
kinase, Nek1, is related to the NIMA cell cycle regulator and
highly expressed in meiotic germ cells. EMBO J. 11:3521–3531.
1992.PubMed/NCBI
|
|
30
|
Upadhya P, Birkenmeier EH, Birkenmeier CS
and Barker JE: Mutations in a NIMA-related kinase gene,
Nek1, cause pleiotropic effects including a progressive
polycystic kidney disease in mice. Proc Natl Acad Sci USA.
97:217–221. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
She QB, Solit DB, Ye Q, O'Reilly KE, Lobo
J and Rosen N: The BAD protein integrates survival signaling by
EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor
cells. Cancer Cell. 8:287–297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ivana Scovassi A and Diederich M:
Modulation of poly(ADP-ribosylation) in apoptotic cells. Biochem
Pharmacol. 68:1041–1047. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bitar KN: HSP27 phosphorylation and
interaction with actin-myosin in smooth muscle contraction. Am J
Physiol Gastrointest Liver Physiol. 282:G894–G903. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bruey JM, Paul C, Fromentin A, Hilpert S,
Arrigo AP, Solary E and Garrido C: Differential regulation of HSP27
oligomerization in tumor cells grown in vitro and in vivo.
Oncogene. 19:4855–4863. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Miki H, Yamada H and Mitamura K:
Involvement of p38 MAP kinase in apoptotic and proliferative
alteration in human colorectal cancers. Anticancer Res.
19:5283–5291. 1999.PubMed/NCBI
|
|
37
|
Abubaker J, Bavi P, Al-Harbi S, Ibrahim M,
Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S,
Al-Dayel F, et al: Clinicopathological analysis of colorectal
cancers with PIK3CA mutations in Middle Eastern population.
Oncogene. 27:3539–3545. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ollikainen M, Gylling A, Puputti M,
Nupponen NN, Abdel-Rahman WM, Butzow R and Peltomäki P: Patterns of
PIK3CA alterations in familial colorectal and endometrial
carcinoma. Int J Cancer. 121:915–920. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Taupin D and Podolsky DK:
Mitogen-activated protein kinase activation regulates intestinal
epithelial differentiation. Gastroenterology. 116:1072–1080. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF,
NRAS, and PIK3CA mutations on the efficacy of cetuximab
plus chemotherapy in chemotherapy-refractory metastatic colorectal
cancer: A retrospective consortium analysis. Lancet Oncol.
11:753–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Herreros-Villanueva M, Chen CC, Yuan SS,
Liu TC and Er TK: KRAS mutations: Analytical considerations.
Clin Chim Acta. 431:211–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Andreyev HJ, Norman AR, Cunningham D,
Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N,
et al: Kirsten ras mutations in patients with colorectal cancer:
The ‘RASCAL II’ study. Br J Cancer. 85:692–696. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Andreyev HJ, Norman AR, Cunningham D,
Oates JR and Clarke PA: Kirsten ras mutations in patients with
colorectal cancer: The multicenter ‘RASCAL’ study. J Natl Cancer
Inst. 90:675–684. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Deng G, Bell I, Crawley S, Gum J, Terdiman
JP, Allen BA, Truta B, Sleisenger MH and Kim YS: BRAF
mutation is frequently present in sporadic colorectal cancer with
methylated hMLH1, but not in hereditary nonpolyposis colorectal
cancer. Clin Cancer Res. 10:191–195. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rajagopalan H, Bardelli A, Lengauer C,
Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis:
RAF/RAS oncogenes and mismatch-repair status. Nature.
418:9342002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Roskoski R Jr: ERK1/2 MAP kinases:
Structure, function, and regulation. Pharmacol Res. 66:105–143.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shama J, Garcia-Medina R, Pouysségur J and
Vial E: Major contribution of MEK1 to the activation of ERK1/ERK2
and to the growth of LS174T colon carcinoma cells. Biochem Biophys
Res Commun. 372:845–849. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hilger RA, Scheulen ME and Strumberg D:
The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie.
25:511–518. 2002.PubMed/NCBI
|
